Press, Neil and Fozard, John R. (2010) Progress Towards Novel Adenosine Receptor Therapeutics Gleaned From The Recent Patent Literature. Expert Opinion On Therapeutic Patents, 20 (8). pp. 987-1005.

Abstract

Importance of the field: The principle of treating disease with selective adenosine receptor ligands has been demonstrated with drugs on the market, while the lesser understood receptor subtypes are still being probed with new and druglike pharmaceutical tools. The field of adenosine receptor research is therefore highly important as an emerging and proven point of intervention in disease.
Areas covered in this review: From 2008-2009, over 120 primary patent applications claimed adenosine receptor ligands, which we analyse by applicant and target. Particularly significant disclosures are described in detail, paying particular attention to the biological data marshalled to support the case.
What the reader will gain: The first published disclosure of new compounds, compound uses or drug targets is often in the patent literature, which can be difficult to trawl, interpret and verify since it is not subject to peer review. We have critically reviewed this area and share our conclusions regarding progress, trends and identification of early tool compounds or compounds of potential clinical significance, ahead of peer-reviewed publication.
Take home message: Adenosine receptor research is a thriving field, with continuing claims of exciting new compounds with high specificity, and intriguing examples of new uses for such ligands.

Item Type:	Article
Keywords:	Adenosine A1, A2A, A2B, A3 receptor ligands, patent analysis, literature search, novel therapeutics
Date Deposited:	13 Oct 2015 13:16
Last Modified:	13 Oct 2015 13:16
URI:	https://oak.novartis.com/id/eprint/2811